Epilepsy drug study for kids halted early: what we know
NCT ID NCT05301894
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at the long-term safety of a drug called NBI-827104 in children with a rare epilepsy that causes seizures during sleep. The trial was stopped early and only enrolled 19 children, so the results are limited. The main goal was to see how many children had serious side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NBI-827104 (a drug that blocks T-type calcium channels in the brain)
What this could lead to
If successful, this could point toward a treatment option for children with this rare form of epilepsy.
What could go wrong
The study was terminated early with only 19 participants, so we have very limited data on safety or effectiveness. It is still in early testing (Phase 2).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPTIC ENCEPHALOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Neurocrine Clinical Site
Orange, California, 92868, United States
-
Neurocrine Clinical Site
Aurora, Colorado, 80045, United States
-
Neurocrine Clinical Site
Washington D.C., District of Columbia, 20010, United States
-
Neurocrine Clinical Site
Miami, Florida, 33155, United States
-
Neurocrine Clinical Site
Rochester, Minnesota, 55905, United States
-
Neurocrine Clinical Site
Durham, North Carolina, 27705, United States
-
Neurocrine Clinical Site
Cleveland, Ohio, 44195, United States
-
Neurocrine Clinical Site
Dianalund, 4293, Denmark
-
Neurocrine Clinical Site
Barcelona, 08950, Spain
-
Neurocrine Clinical Site
Madrid, 28034, Spain
-
Neurocrine Clinical Site
Zurich, 8032, Switzerland
-
Neurocrine Clinical Site
London, WC1N 3JH, United Kingdom